Literature DB >> 30610434

The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.

Signe Harder1,2,3, Jørn Herrstedt4,5, Jesper Isaksen6, Mette Asbjoern Neergaard7, Karin Frandsen8, Jarl Sigaard9, Lise Mondrup9, Bodil Abild Jespersen7, Mogens Groenvold8,10.   

Abstract

BACKGROUND: The prevalence of nausea/vomiting in patients with advanced cancer has a wide range. Due to a very low level of evidence regarding antiemetic treatment, current guidelines recommend an etiology-based approach. The evidence for this approach is also slim and research is urgently needed.
OBJECTIVES: (Part One) to elucidate the prevalence of nausea and the possible associations with sociodemographic and clinical variables and (Part Two) to investigate possible etiologies of nausea and antiemetic treatments initiated in patients with nausea.
METHODS: Patients with advanced cancer and no recent antineoplastic treatment were included in a prospective two-part study. In Part One, patients completed an extended version of the EORTC QLQ-C15-PAL. Nauseated patients could then be included in Part Two in which possible etiologies and antiemetic treatment were recorded and a follow-up questionnaire was completed.
RESULTS: Eight hundred twenty-one patients were included and 46% reported any degree of nausea. Younger age and female sex were associated with a higher degree of nausea. Common etiologies included constipation, opioid use, and "other," and treatments associated with a statistically significant decrease in nausea/vomiting were olanzapine, laxatives, corticosteroids, domperidone, and metoclopramide.
CONCLUSION: Nausea was a common symptom in this patient population and many different etiologies were suggested. Most patients reported a lower degree of nausea at follow-up. More research in treatment approaches and specific antiemetics is strongly needed.

Entities:  

Keywords:  Advanced cancer; Etiology; N/V; Nausea; Treatment

Mesh:

Substances:

Year:  2019        PMID: 30610434     DOI: 10.1007/s00520-018-4623-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  5 in total

1.  Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study.

Authors:  Isseki Maeda; Eriko Satomi; Daisuke Kiuchi; Kaoru Nishijima; Yoshinobu Matsuda; Akihiro Tokoro; Keita Tagami; Yoshihisa Matsumoto; Akemi Naito; Tatsuya Morita; Satoru Iwase; Hiroyuki Otani; Takuya Odagiri; Hiroaki Watanabe; Masanori Mori; Yosuke Matsuda; Hiroka Nagaoka; Meiko Mayuzumi; Yoshiaki Kanai; Nobuhiro Sakamoto; Keisuke Ariyoshi
Journal:  Support Care Cancer       Date:  2021-03-20       Impact factor: 3.603

2.  Nausea at the start of specialized palliative care and change in nausea after the first weeks of palliative care were associated with cancer site, gender, and type of palliative care service-a nationwide study.

Authors:  Maiken Bang Hansen; Mathilde Adsersen; Leslye Rojas-Concha; Morten Aagaard Petersen; Lone Ross; Mogens Groenvold
Journal:  Support Care Cancer       Date:  2022-08-12       Impact factor: 3.359

Review 3.  Nausea and Vomiting: a Palliative Care Imperative.

Authors:  Rita J Wickham
Journal:  Curr Oncol Rep       Date:  2020-01-20       Impact factor: 5.075

4.  The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature.

Authors:  G Saudemont; C Prod'Homme; A Da Silva; S Villet; M Reich; N Penel; V Gamblin
Journal:  BMC Palliat Care       Date:  2020-04-22       Impact factor: 3.234

Review 5.  The Benefits of Olanzapine in Palliating Symptoms.

Authors:  Mellar P Davis; Gareth J Sanger
Journal:  Curr Treat Options Oncol       Date:  2020-11-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.